Founded in 1992, MorphoSys has developed and established one of the world’s leading fully human antibody technologies. Numerous partnerships with well-known companies from the pharmaceutical and biotechnology sector, such as Boehringer Ingelheim, Daiichi Sankyo, Merck, Novartis, Pfizer and Roche illustrate our success.
With the help of our proprietary, industry-leading antibody technologies, almost 300 employees are dedicated to engineering the medicines of tomorrow. The highly qualified staff collaborate closely to streamline and coordinate product research and development with all its accompanying processes.
The Management Board and the Supervisory Board of MorphoSys are committed to creating significant value for all employees, shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potential.